查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138391

显微镜下多血管炎 (MPA) 治疗的全球市场 - 2022-2029

Global Microscopic Polyangiitis (MPA) Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球显微多血管炎 (MPA) 治疗市场的增长是由慢性病患病率上升和人口老龄化、细胞分离技术进步、对生物製药的需求增加推动的，干细胞研究是由某些因素驱动的，例如增加在市场增长的一些主要驱动力是：

微型多血管炎 (MPA) 新疗法的不断发展和强大的管道药物预计将在预测期内推动全球微型多血管炎 (MPA) 治疗市场。

治疗显微镜下多血管炎的在研药物包括阿巴西普和 IFX 1。 2018年7月，德国临床阶段生物製药公司InflaRx N.V.向美国食品药品监督管理局宣布，将开展IFX-1治疗抗中性粒细胞胞浆自身抗体（ANCA）血管炎的2期临床试验。（FDA） ) 清除，ANCA 的存在表明患者患有微血管炎 (MPA)。 IFX-1是补体系统的抑製剂，可以中和C5a成分而不影响正常的免疫功能。因此，预计在预测期内增加用于开发 MPA 新疗法的临床试验将促进微观多血管炎市场的增长。

美国食品药品监督管理局 (FDA)、欧洲药品管理局 (EMA) 和药品和保健品监管机构 (MHRA) 等监管机构越来越多地批准用于治疗 MPA 的多种药物将推动市场增长。我正在进一步推动。例如，2018 年 10 月，Genentech 患有肉芽肿性多血管炎和显微镜下多血管炎 (MPA)，通过糖皮质激素和环磷□胺的诱导治疗得到改善。获得美国食品和药物管理局 (FDA) 批准更新 Rituxan 的标籤以包括后续治疗成人患者的信息。

阻碍显微镜下多血管炎 (MPA) 治疗市场增长的药物相关副作用

然而，全球微观多血管炎市场的增长受到多种因素的阻碍，包括药物引起的副作用。肾上腺皮质激素引起的副作用包括皮肤变薄和剧烈疼痛。单克隆抗体的生产需要昂贵且耗时的研究。硫唑嘌呤与副作用有关，例如腹泻、关节疼痛、失去协调、癫痫发作和视力改变。

行业分析

全球微观多血管炎（MPA）治疗市场基于波特五力分析、供应链分析、监管分析、定价分析、专利分析、流行病学和未满足需求等多种行业因素，提供了深入的市场分析。

全球显微多血管炎 (MPA) 治疗市场报告提供了大约 40 多个市场数据表、45 多个图表和 180 页的结构。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按药物划分的市场细分
  • 按管理途径划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
  • 驱动程序
    • 增加研发投入
    • 在研药物增加
  • 限制因素
    • 药物的副作用
  • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 流行病学
  • 管道分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 未满足的需求

第六章药物

  • 利妥昔单抗（利妥昔单抗）
  • 环磷□胺（环磷□胺）
  • 硫唑嘌呤
  • 泼尼松
  • 阿巴科麵包
  • 其他

第 7 章给药途径

  • 口语
  • 注入

第 8 章按分销渠道

  • 医院药房
  • 零售药房
  • 在线药店

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 11 章公司简介

  • Celltrion Inc.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • ChemoCentryx Inc.
  • Teijin Pharma Ltd.
  • Sandoz International GmbH
  • Genentech, Inc.
  • InflaRx N.V.
  • Bristol-Myers Squibb Company
  • Amerigen Pharmaceuticals Limited
  • TTY Biopharm Company Ltd.

第12章 DataM

简介目录
Product Code: DMPH2601

Market Overview

Microscopic Polyangiitis (MPA) Treatment Market size was valued at US$ XX billion in 2021 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of 5.5% during the forecast period (2022-2029).

Microscopic polyangiitis (MPA), known as ANCA-associated vasculitis, is a rare disorder characterized by inflammation of the blood vessels that restricts the blood flow and damage vital organs and tissues. Some other forms of ANCA-associated vasculitis include eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA). MPA mostly affects the small to medium-sized blood vessels, particularly involving the kidneys, lungs, nerves, skin, and joints. It can worsen rapidly, so early diagnosis and treatment are essential to prevent kidney or respiratory damage or organ failure.

Microscopic polyangiitis can affect both men and women of all ages, but the average age is around 50, and men may get MPA more often. MPA is rare, with prevalence at 1 to 3 cases per 100,000 people in the United States. The incidence is around 2 cases per 100,000 people in the United Kingdom and an estimated 1 case per 100,000 people in Sweden.

MPA is diagnosed by several tests including, the blood test for antineutrophil cytoplasmic antibodies (ANCA), urine test for diagnosis of red blood cells (RBCs), and imaging procedures such as computed tomography (CT), magnetic resonance (MR) scan, and X-rays. If these tests are positive for the presence of MPA, biopsy (tissue sample testing) is performed to confirm the presence of MPA.

Market Dynamics

The global microscopic polyangiitis (MPA) treatment market growth driven by certain factors such as rising prevalence of chronic diseases with growing geriatric population, technological advancement in cell isolation, increasing demand for biopharmaceuticals, and increasing stem cell research. are among the key factors driving the market growth.

Rising development of new treatments for MPA and robust pipeline drugs, is expected to drive the global microscopic polyangiitis (MPA) treatment market during the forecast period

Some of the pipeline drugs for treating microscopic polyangiitis are Abatacept, IFX 1, among others. In July 2018, InflaRx N.V., a German clinical-stage bio-pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for conducting phase II clinical trials of IFX-1 for treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of ANCA indicates that the patient is suffering from microscopic polyangiitis (MPA). IFX-1, an inhibitor of the complement system, neutralizes the C5a component without affecting the normal immune functions. Hence, increasing clinical trials for the development of new treatments for MPA is expected to boost the microscopic polyangiitis market's growth over the forecast period.

The increasing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), among others for several drugs for the treatment of MPA, is further driving the growth of the market. For instance, in October 2018, Genentech received the U.S. Food and Drug Administration (FDA) approval to update the Rituxan label to include the follow-up treatment information of adult patients suffering from granulomatosis with polyangiitis and microscopic polyangiitis (MPA), who had shown improvement in medical condition with the glucocorticoid and cyclophosphamide induction treatment.

Side-effects associated with the drugs hampering the growth of the microscopic polyangiitis (MPA) treatment market

However, the global microscopic polyangiitis market growth is hindered by some factors, including side-effects caused by the drugs. Some of the side-effects caused by corticosteroids include skin thinning and intense pain. Monoclonal antibody production involves costly and time-consuming research. Azathioprine involves side effects such as diarrhea, joint pain, loss of coordination, seizure, and vision changes.

Industry Analysis

The global microscopic polyangiitis (MPA) treatment market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, pricing analysis, patent analysis, epidemiology, unmet needs.

Segment Analysis

The drug segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The treatment of microscopic polyangiitis is based on several factors, including disease severity and organ involvement. Commonly, MPA is treated with corticosteroids such as prednisone combined with other medications that suppress the immune system and reduce inflammation. However, even with treatment, MPA is a chronic condition with periods of relapse and remission, so ongoing medical care and monitoring are necessary. Some of the drugs available for MPA treatment are Rituximab (Rituxan), Cyclophosphamide (Cytoxan), Azathioprine, Prednisone, Avacopan, and others. In 2011, the U.S. Food and Drug Administration (FDA) approved rituximab to treat MPA and GPA. (Biologic medications are complex proteins derived from living organisms. They target certain parts of the immune system to control inflammation.). Rituximab is expected to gain maximum share over the forecast period (2020-2027).

On the other hand, cyclophosphamide is growing at a significant growth rate over the forecast period. It is a chemotherapy-type drug that blocks the abnormal growth of certain cells in the body in combination with prednisone. Prednisone is typically started at a high dose and then tapered off slowly. Cyclophosphamide lowers the body's ability to fight infection, hence usually limited to a three- to six-month period and replaced by less toxic medications such as mycophenolate mofetil azathioprine, or methotrexate, a drug commonly used to treat rheumatoid arthritis. Some milder forms of MPA are typically treated with a combination of prednisone and methotrexate.

Geographical Analysis

North America region holds the largest market share of the global microscopic polyangiitis (MPA) treatment market

North American region is dominating the global microscopic polyangiitis (MPA) treatment market accounting for the maximum market share in 2022 due to the increasing development of drugs to treat MPA. In the United States, the annual incidence of microscopic polyangiitis is 3.6 cases per million persons, and the prevalence is one to three cases per 100,000 population. In September 2022, Roche received the U.S. Food and Drug Administration (FDA) approval for Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in pediatric patients two years of age and older.

Competitive Landscape

The microscopic polyangiitis (MPA) treatment market is highly competitive and consists of several major players and new players in the market. Some of the key players which are contributing to the growth of the market are ChemoCentryx Inc., Celltrion, Inc., Teijin Pharma Ltd, Sandoz International GmbH (Novartis Division), TTY Biopharm Company Ltd, Genentech, Inc., InflaRx N.V., Bristol-Myers Squibb Company, Amerigen Pharmaceuticals Limited, among others. The major players are adopting several growth strategies such as product launches, clinical trials, acquisitions, and collaborations, contributing to the growth of the microscopic polyangiitis (MPA) treatment market globally. For instance,

On 4th May 2020, Israeli generics giant Teva Pharmaceutical Industries and partner, South Korean biotechnology company Celltrion, launched their rituximab biosimilar Truxima (TL011) in the US. Truxima (rituximab-abbs) is now available in the US for the treatment of patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's granulomatosis), and microscopic polyangiitis.

In January 2020, Pfizer announced to introduce three new biosimilars this year. The company plans to launch Avastin biosimilar Zirabev (bevacizumab-bvzr), Rituxan biosimilar Ruxience (rituximab-pvvr), and Herceptin biosimilar Trazimera (trastuzumab-qyyp). The audience is available to treat adult patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Key Companies to Watch

Celltrion Inc

Overview: Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Jung Jin Seo, is the richest person in South Korea.

Product Portfolio: Truxima (rituximab)- Targets a specific protein in the immune system that may trigger inflammation of the blood vessels.

The global microscopic polyangiitis (MPA) treatment market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Drug
  • 3.2. Market Snippet by Route of Administration
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising R&D investments
    • 4.2.2. The growing number of pipeline drugs
    • 4.2.3. XX
  • 4.3. Restraints:
    • 4.3.1. Side-effects caused by drugs
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs

6. By Drug

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 6.1.2. Market Attractiveness Index, By Drug Segment
  • 6.2. Rituximab (Rituxan)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.3. Cyclophosphamide (Cytoxan)
  • 6.4. Azathioprine
  • 6.5. Prednisone
  • 6.6. Avacopan
  • 6.7. Others

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 7.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 7.2. Oral*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Injectable

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 8.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 8.2. Hospital pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Retail pharmacies
  • 8.4. Online pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. The U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. The Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Celltrion Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. ChemoCentryx Inc.
  • 11.3. Teijin Pharma Ltd.
  • 11.4. Sandoz International GmbH
  • 11.5. Genentech, Inc.
  • 11.6. InflaRx N.V.
  • 11.7. Bristol-Myers Squibb Company
  • 11.8. Amerigen Pharmaceuticals Limited
  • 11.9. TTY Biopharm Company Ltd.

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us